David Baker’s Technology Transfer and Advisory Roles

Updated 4-11-19

David Baker’s conflict of interest management plan is provided by UW and HHMI.

David Baker is a co-founder, shareholder, or advisor to the following companies.  The first date on each line indicates the year of Company founding. (In parentheses are the dates & focus of David Baker’s involvement.) Founder = F, Advisor = A

ARZEDA Seattle WA 2009 (2009-present, F, A) Enzyme design engineering for agribusiness and fine chemicals.

PvP Biologics Seattle WA 2013 (2013-present, F, A)  Designed enzyme therapeutic for celiac disease.

Cyrus Biotech: Seattle WA 2014 (2014-present, F, A) Cloud based software for biomolecular design.

Cue Biopharma Boston MA 2014 (2014-present, A) Biologic immunotherapies.

Icosavax  Seattle WA 2017 (2017-present, F, A) Designed protein nanoparticle vaccines.

Neoleukin Therapeutics  Seattle WA 2018 (2018-present, F, A) Designed proteins immunoncology.

Sana Biotechnology  Seattle WA / San Francisco CA / Boston MA 2018 (2018-present, F, A) Creating and delivering engineered cells as medicine for patients.

Lyell Immunotherapeutics:  Seattle WA / San Francisco CA 2018 (2018-present, F, A) Developing engineered T-cells designed to eliminate solid cancers.

A-Alpha Bio  Seattle WA  2018 (2018-present, F, A) Developing a fundamentally new way of supporting safer drug discovery.

Companies licensing Baker lab patents or software:

PvP Biologics: Seattle / San Diego based company focused on the development of oral enzyme therapeutics for celiac disease, computationally designed enzymes that breakdown gluten in the stomach.

Cyrus Biotech: Seattle based company commercializing a user friendly Rosetta GUI for computational protein structure prediction and design – software as a service in the cloud solution for biotechnology and pharmaceutical research.

Icosavax:  Seattle based company focused on development of a designed protein nanoparticle vaccine for respiratory syncytial virus (RSV) and other infectious diseases.

Neoleukin Therapeutics: Seattle based company developing an array of new proteins that activate the immune system to attack the worst types of cancer.

Lyell Immunotherapeutics:  Seattle / San Francisco based company developing engineered T-cells designed to eliminate solid cancers.

Sana Biotechnology:  Seattle / San Francisco  / Boston based company creating and delivering engineered cells as medicine for patients.

A-Alpha Bio:  Seattle based company developing a fundamentally new way of supporting safer drug discovery.

Rosetta  Licensing is manged by UW CoMotion, and royalty proceeds are managed by the Rosetta Commons.  Rosetta software has been licensed to numerous non-profit and for profit organizations.